With breakthrough discoveries addressing patients’ unmet needs, caregivers, decision-makers, and advocacy groups have made great strides towards bringing patient experience to the mainstream.
Today’s guest is TJ Sharpe, a Patient Insights Expert and Stage-IV Melanoma survivor. In his topic “Complicating is easy, Simplifying is Difficult, the personalized patient experience”, T.J. will shed light on patient engagement, personalized patient experience, and major roadblocks in clinical research at Reuters Pharma USA 2025.
T.J. presents a holistic approach for Sponsors to engage patients in clinical trials by testing smaller groups, collaborating with advocacy groups, and understanding the patient journey to enhance the patient experience.
Image Source: Canva
About the Author:
T.J. Sharpe
T.J. Sharpe is a Stage IV melanoma survivor who began sharing his journey through cancer as a blogger and later a keynote speaker. Diagnosed in August 2012 and given two years to live, he has undergone six surgeries and four immunotherapy treatments over two different clinical trials. His story of overcoming numerous issues to find, select, enroll, and complete two trials illustrates the hurdles many patients encounter when faced with a difficult diagnosis.
Taking his personal journey and the insights gleaned from a decade+ of listening to and working with leaders in healthcare, clinical research, digital medicine technologies, and patient advocacy, he speaks frankly about and works tirelessly towards creating advanced patient engagement to benefit all.
Now a speaker, writer, and patient expert consultant, he has worked with top pharmaceutical companies and clinical research stakeholders to address the power imbalance in patient care through sustained, ingrained, and consistent patient engagement. A South Jersey native, T.J. lives in Fort Lauderdale with his wife Jennifer and two children, Josie and Tommy. He is active on Twitter at @TeamTJSharpe and LinkedIn at https://www.linkedin.com/in/tjsharpe/.
Related Post: Reuters Events: Pharma USA 2025
